CGON Stock: Price, Earnings History and SEC Filings
CG Oncology, Inc. (CGON) last traded at $64.68, up 1.91% on the latest session and down 8.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.90 against an analyst estimate of $-0.70, a miss of 28.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CGON earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.90 | $-0.70 | -28.57% |
| Mar 2026 | May 8, 2026 | $-0.71 | $-0.58 | -22.41% |
| Dec 2025 | Feb 27, 2026 | $-0.51 | $-0.61 | +16.39% |
| Sep 2025 | Nov 14, 2025 | $-0.57 | $-0.57 | +0.00% |
CGON beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How CGON reacts to earnings
Across its last 8 earnings releases, CGON moved 4.0% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +3.36% |
| 2026-05-08 | Before open | +0.64% |
| 2026-02-27 | Before open | +4.79% |
| 2025-11-14 | Before open | +8.61% |
| 2025-08-08 | Before open | +2.05% |
| 2025-05-13 | Before open | -3.90% |
| 2025-03-28 | Before open | -1.93% |
| 2024-11-12 | Before open | -6.83% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CGON financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4M | -$161M | -$132M | -3985.0% | $-2.08 |
| 2024 | $1M | -$88M | -$79M | -7729.5% | $-1.41 |
| 2023 | $204000 | -$49M | – | -23827.0% | $-15.65 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CGON
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Other events, Financial statements and exhibits
- 424B5 · Aug 6, 2026
- 8-K · Jun 8, 2026Shareholder vote
- 8-K · May 26, 2026Officer or director change
- 10-Q · May 8, 2026
- 8-K · May 8, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 8-K · Apr 13, 2026Officer or director change, Financial statements and exhibits
- 10-K · Feb 27, 2026
Insider filing activity
CGON insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CGON news
No recent headlines found. The live terminal has the full news feed.
About CG Oncology, Inc.
CG Oncology, Inc. (CGON) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.